Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer
Menée in vitro et à l'aide de xénogreffes, cette étude met en évidence des mécanismes par lesquels la rapamycine favorise l'efficacité du navitoclax dans le traitement d'un cancer du poumon à petites cellules
Over-expression of the anti-apoptotic protein Bcl-2 is observed in the majority of small cell lung cancer (SCLC) cases and is associated with resistance to chemotherapy. While targeting Bcl-2 in hematologic malignancies continues to show signs of promise, translating the BH3 mimetic ABT-737 (or ABT-263; navitoclax) to the clinic for solid tumors has remained problematic, with limited single agent activity in early phase clinical trials. Here we used patient-derived xenograft (PDX) models of SCLC to study ABT-737 resistance and demonstrated that responses to ABT-737 are short-lived and coincide with decreases in HIF-1α regulated transcripts. Combining the mTOR inhibitor rapamycin with ABT-737 rescued this resistance mechanism, was highly synergistic in vitro, and provided durable tumor regressions in vivo without notable hematologic suppression. In comparison, tumor regressions did not occur when ABT-737 was combined with etoposide, a gold standard cytotoxic for SCLC therapy. Rapamycin exposure was consistently associated with an increase in the pro-apoptotic protein BAX, whereas ABT-737 caused dose-dependent decreases in BAX. As ABT-737 triggers programmed cell death in a BAX/BAK-dependent manner, we provide pre-clinical evidence that the efficacy of ABT-737 as a single agent is self-limiting in SCLC, but the addition of rapamycin can maintain or increase levels of BAX protein and markedly enhance the anti-cancer efficacy of ABT-737. These data have direct translational implications for SCLC clinical trials.